Table 3.
Efona success rate.
| Study | Number of eFONA cases | Number of successful eFONA | Success rate% (95% CI) |
|---|---|---|---|
| Pre-hospital | |||
| Spaite (1990) | 16 | 14 | 88% (62–98) |
| Boyle (1993) | 69 | 68 | 99% (92–99) |
| Xeropotamos (1993) | 11 | 11 | 100% (71–100*) |
| Jacobson (1996) | 50 | 47 | 94% (83–98) |
| Gerich (1998) | 8 | 8 | 100% (63–100*) |
| Thomas (1999) | 10 | 9 | 90% (55–99) |
| Robinson (2001) | 8 | 5 | 63% (24–91) |
| Warner (2009) | 10 | 9 | 90% (55–99) |
| Germann (2009) | 6 | 6 | 100% (54–100*) |
| Wang (2011) | 88 | 61 | 69% (58–78) |
| Kamiutsuri (2013) | 13 | 11 | 85% (54–98) |
| Diggs (2014) | 1332 | 457 | 34% (31–36) |
| Brown (2014) | 35 | 34 | 97% (85–99) |
| Schober (2019) | 230 | 216 | 94% (89–96) |
| Aziz (2021) | 11 | 10 | 91% (58–99) |
| In-hospital | |||
| Gillespie (1999) | 35 | 34 | 97% (85–99) |
| Wong (2008) | 8 | 7 | 88% (47–99) |
| Cook (2011) | 58 | 21 | 36% (23–49) |
| NAP4 (2011) | 58 | 50 | 86% (74–93) |
| Beshey (2014) | 169 | 163 | 96% (92–98) |
| Darby (2016) | 22 | 20 | 91% (70–98) |
| Rosenstock (2016) | 27 | 21 | 78% (57–91) |
| Kwon (2019) | 23 | 17 | 74% (51–89) |
| Pre-hospital/In-hospital | |||
| Nugent (1991) | 55 | 53 | 96% (87–99) |
| Salvino (1993) | 30 | 30 | 100% (88–100*) |
| Bair (2003) | 50 | 50 | 100% (92–100*) |
| McIntosh (2008) | 17 | 17 | 100% (80–100*) |
| Graham (2011) | 94 | 94 | 100% (96–100*) |
| Paix (2012) | 24 | 24 | 100% (85–100*) |
| Katzenell (2012) | 46 | 43 | 93% (82–98) |
| Duggan (2018) | 99 | 71 | 72% (61–80) |
| High (2018) | 13 | 13 | 100% (75–100*) |
| Moroco (2021) | 12 | 7 | 58% (27–84) |
| Battlefield | |||
| Leibovici (1997) | 29 | 26 | 90% (72–97) |
| Adams (2008) | 17 | 13 | 76% (50–93) |
| Mabry (2012) | 72 | 49 | 68% (56–78) |
| Barnard (2014) | 34 | 28 | 82% (65–93) |
| Kyle (2016) | 86 | 79 | 92% (83–96) |
| Benov (2019) | 30 | 25 | 83% (65–94) |
| Beit Ner (2021) | 153 | 135 | 88% (82–92) |
*
One-sided, 97.5% confidence interval.